TY - JOUR
KW - Buprenorphine, Naloxone Drug Combination/therapeutic use
KW - Humans
KW - Medicaid
KW - Naltrexone/therapeutic use
KW - Opioid-Related Disorders/drug therapy
KW - Retrospective Studies
KW - United States
AU - G. Cochran
AU - E. S. Cole
AU - M. Sharbaugh
AU - D. Nagy
AU - A. J. Gordon
AU - W. F. Gellad
AU - J. Pringle
AU - T. Bear
AU - J. Warwick
AU - C. Drake
AU - C. H. Chang
AU - E. DiDomenico
AU - D. Kelley
AU - J. Donohue
A1 - 
AD - Department of Internal Medicine, University of Utah, City, UT (GC, AJG), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (ESC, MS, DN, TB, CD, JD), School of Medicine, University of Pittsburgh, Pittsburgh, PA (WFG, C-CH), Program Evaluation Research Unit, University of Pittsburgh, Pittsburgh, PA (JP, JW), School of Pharmacy, University of Pittsburgh, Pittsburgh, PA (JP), Pennsylvania Department of Drug and Alcohol Programs, Harrisburg, PA (ED), Pennsylvania Department of Human Services, Harrisburg, PA (DK).
BT - Journal of addiction medicine
C5 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
CP - 2
CY - United States
DO - 10.1097/ADM.0000000000000859
IS - 2
JF - Journal of addiction medicine
LA - eng
M1 - Journal Article
PB - American Society of Addiction Medicine
PP - United States
PY - 2022
SN - 1935-3227; 1932-0620
SP - e87
EP - e96
EP - 
T1 - Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder
T2 - Journal of addiction medicine
TI - Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder
U1 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U2 - 33973921
U3 - 10.1097/ADM.0000000000000859
VL - 16
VO - 1935-3227; 1932-0620
Y1 - 2022
Y2 - Mar-Apr 01
ER -